SynthesisScientific reports2025
Predictive and clinicopathological importance of HMGB2 in various carcinomas: a meta and bioinformatic approach.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer.Pharmaceutics · 2026Article
- From cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles.Cell communication and signaling : CCS · 2026Article
- Living Cells Employ Ubiquitin-Proteasomal System and Nucleotide Excision Repair Pathways to Remove Reactive Oxygen Species-Induced DNA-Protein Crosslinks (ROS-DPCs).bioRxiv : the preprint server for biology · 2026Article
- Mechanisms of lactylation modification in hepatocellular carcinoma treatment resistance.Gastroenterology report · 2026Review
- Decoding the role of cancer stem cells in digestive tract tumors: Mechanisms and therapeutic implications (Review).International journal of oncology · 2025Review
- LMNA-NTRK1-rearranged spindle cell neoplasm with multiple relapses: a case report and literature review.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh mobility group box 2 (HMGB2), one of the HMGB domain proteins, may play a significant role in cancer development and progression. Recent scientific investigations have hinted at the potential clinical relevance of HMGB2, particularly in cancer patients where its expression levels have been observed to be elevated. However, the precise impact of HMGB2 on the prognosis of tumors remains an area of ongoing research. To the best of our understanding, our study represents a meta-analysis that elucidates a connection between HMGB2 expression and the clinical outcomes of diverse cancer types.
methodWe executed a thorough and systematic search of literature across PubMed, Web of Science, Embase, CNKI, and Wanfang databases. Following this, we conducted a quantitative meta-analysis using statistical tools such as StataMP16 and RevMan5.3. The primary focus of our analysis was to assess the relationship between HMGB2 expression levels and overall survival (OS), disease-free survival (DFS), as well as various clinicopathological characteristics of cancer patients by calculating the hazard ratio (HR). Additionally, we validated our findings by examining HMGB2 expression patterns across different cancer types using the Gene Expression Profiling Interactive Analysis (GEPIA) online platform.
resultOur meta-analysis incorporated data from 17 studies, encompassing a total of 2555 cancer patients. The results revealed a statistically significant association between high HMGB2 expression and shorter OS (HR, 1.40 ;95% CI: 1.10-1.70; P < 0.001), especially in digestive cancer ( HR, 2.09 (95% CI: 1.54-2.63; I
conclusionOur findings underscore a detrimental correlation between the upregulation of HMGB2 and the prognosis of various cancers. This discovery could pave the way for the development of innovative prognostic biomarkers and therapeutic targets that specifically target HMGB2, offering new avenues for the management and treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.